Wilson Therapeutics AB

Rising Leaders Home HealthCap is a family of venture capital funds that has invested more than €1.2bn in life sciences since its inception in 1996. Co-managing partner Mårten Steen, one of In Vivo ’

AstraZeneca PLC ’s rare disease unit Alexion has announced positive results with ALXN1840 in the Phase III FoCus study in Wilson disease, and the compound is expected to be submitted for marketing app

Aldeyra Therapeutics’ Reproxalap Indication: Allergic conjunctivitis Phase III data for Aldeyra Therapeutics Inc. ’s reproxalap, an immune-modulating covalent inhibitor of reactive aldehyde species

Plagued by clinical setbacks with its lead asset PledOx for chemotherapy-induced peripheral neuropathy, PledPharma AB has opted to focus on the orphan drug segment and acquire fellow Swedish firm R